We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Patent and Trademark Office’s recently established patent review board has received what appears to be its first challenge to a drug patent covering a business practice rather than a drug’s attributes. Read More
Generic drugmaker Mylan agreed to pay Abbott Labs $5.3 billion in stock to acquire part of its international generic drug business in a deal that vastly spreads the geographic reach of the Pennsylvania-based firm. Read More
Pfizer is facing at least three class action lawsuits alleging that the company went to extraordinary, fraudulent lengths to maintain exclusivity over its multibillion dollar arthritis pain drug Celebrex and keep generic competitors off the market. Read More
Generic drugmaker Mylan agreed to pay Abbott Labs $5.3 billion in stock to acquire part of its international generic drug business in a deal that vastly spreads the geographic reach of the Pennsylvania-based firm. Read More
Canadian pharmaceutical company Duchesnay has filed a lawsuit against generic manufacturer Actavis over its challenge to Duchesnay’s morning sickness drug Diclegis. Read More
Iowa’s Supreme Court once again confirmed that brand manufacturers can’t be held liable for injuries sustained when patients take a generic version of their drug. Read More
Colorado-based Allos Therapeutics and three research organizations are suing Dr. Reddy’s over its proposed generic version of the brand manufacturer’s orphan lymphoma drug Folotyn. Read More
A federal judge this week struck down Massachusetts’ recently enacted prescribing restrictions on Zogenix’s opioid painkiller Zohydro ER — restrictions that the drugmaker argued had effectively made the therapy unavailable and contravened the FDA’s right to approve drugs it considers safe and effective. Read More